Yazarlar : Schiller GJ.

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : Leuk Lymphoma

Konu : Lösemi

Literatür İçeriği :  Abstract Acute myeloid leukemia (AML) comprises a set of biologically distinct diseases characterized by maturation arrest and clonal proliferation. Recommendations for postremission therapy depend on assessing the leukemia risk characteristics, such as cytogenetics and molecular features present at diagnosis. High-risk patients include those whose leukemia is characterized by monosomal karyotype or poor-risk cytogenetic or molecular abnormalities; patients with antecedent hematologic disorders or therapy-related AML; and presence of adverse host factors, such as comorbidities, impaired performance status, or older age. Older patients are more likely to have these adverse features. High-risk AML responds poorly to available induction treatment and is likely to relapse despite consolidation therapy. Current data support an increasing understanding of prognosis but have not yet resulted in effective therapies for high-risk patients. This review discusses current therapies and evolving treatment strategies for high-risk AML.

Literatür Arşivi